drugset / Trial / NCT00244608

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

NCT00244608

Phase 3 Completed 100 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

Timeline

Start
2005-05
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Budesonide Small molecule 320 ug Inhaled
Subject Budesonide Small molecule 400 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled
Subject Terbutaline Small molecule 0.4 mg Inhaled

Indications